MRNA vs VRTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
VRTX Captures Institutional Edge (2โ2 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Vertex Pharmaceuticals Inc (VRTX) driven by superior Growth & Margin, Options & Structure while MRNA counters with relative strength in Valuation, Momentum & Technical. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus VRTX at 25.9x Forward P/E and 37.8% operating margin (+11.8% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against VRTX sits in CONSOLIDATION (33rd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MRNA Revenue | VRTX Revenue | MRNA Op. Margin | VRTX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $140M | $3.05B | -306.0% | 20.8% | VRTX |
| FY2019 | $60M | $4.16B | -906.8% | 28.8% | VRTX |
| FY2020 | $800M | $6.21B | -95.0% | 46.0% | VRTX |
| FY2021 | $18.5B | $7.57B | 72.0% | 36.7% | MRNA |
| FY2022 | $19.3B | $8.93B | 48.9% | 48.2% | MRNA |
| FY2023 | $6.85B | $9.87B | -61.9% | 38.8% | VRTX |
| FY2024 | $3.24B | $11.0B | -121.9% | -2.1% | VRTX |
| FY2025 | $1.94B | $12.0B | -158.1% | 34.8% | VRTX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MRNA | VRTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $80.7B | $132.0B | Larger Scale | VRTX |
| Trailing P/E Ratio Valuation | 23.0x | 33.5x | Lower Multiple | MRNA |
| Forward P/E Ratio Valuation | 23.0x | 25.9x | Lower Multiple | MRNA |
| Revenue Growth (YoY) Growth | +29.2% | +11.8% | Higher Growth | MRNA |
| Operating Margin (TTM) Profitability | -80.8% | 37.8% | Higher Margin | VRTX |
| Net Profit Margin Profitability | -110.5% | 30.7% | Higher Margin | VRTX |
| Return on Equity (ROE) Capital Efficiency | -34.5% | 20.8% | Higher ROE | VRTX |
| 52-Week Range Position Momentum | 67% ($22โ$281) | 66% ($412โ$569) | Stronger Trend | MRNA |
| Beta / 30D Volatility Risk Regime | 2.23ฮฒ ยท 78% Vol | 0.35ฮฒ ยท 28% Vol | Lower Realized Risk | VRTX |
| Unified Institutional Score Composite Signal | 40.3 / 100 (SELL) | 40.9 / 100 (SELL) | Higher Composite | VRTX |